ELDRED KARY 4
4 · GALECTIN THERAPEUTICS INC · Filed Feb 9, 2026
Research Summary
AI-generated summary of this filing
Galectin Therapeutics Director Kary Eldred Buys 300 Shares
What Happened Kary Eldred, a director of Galectin Therapeutics (GALT), reported a purchase of 300 shares on February 6, 2026. The shares were acquired at $2.70 each for a total reported purchase value of $810. This was a purchase (transaction code P), which represents an insider buy rather than a sale.
Key Details
- Transaction date: 2026-02-06; Filing date: 2026-02-09 (timely filing).
- Price and quantity: 300 shares at $2.70 per share; total = $810.
- Transaction type: P = Purchase (open market or private purchase as reported).
- Shares owned after the transaction: Not specified in the provided filing.
- Footnotes:
- F1 — These shares are held of record by Eldred as custodian for a minor under the Uniform Transfer to Minors Act; Eldred disclaims beneficial ownership.
- F2 — These shares are also held in a special needs trust for which Eldred is trustee; Eldred disclaims beneficial ownership.
- No indication of a 10b5-1 plan, option exercise, gift, or tax-withholding event in this filing.
Context The reported purchase is small in dollar value ($810) and appears to reflect shares held in custodial/trust capacities rather than direct beneficial ownership by the director. Purchases can be informative to investors, but the filing’s footnotes clarify Eldred disclaims beneficial ownership of these specific shares.
Insider Transaction Report
- Purchase
Common Stock
2026-02-06$2.70/sh+300$810→ 65,682 total
- 2,425(indirect: By Children)
Common Stock
[F1] - 2,000(indirect: By Trust)
Common Stock
[F2]
Footnotes (2)
- [F1]These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.
- [F2]These shares are held in a special needs trust for which the Reporting Person serves as a trustee. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.